More than 20 studies have been performed to confirm the safety and efficacy of PreforPro. In-vitro and in-vivo tests have demonstrated the growth-promoting effect of PreforPro on beneficial bacterial strains of Lactococcus, Lactobacillus, Bifidobacterium and Bacillus subtilis when competing with undesirable bacterial strains.

Promoting Probiotic Growth

In in vitro tests under physiological conditions, PreforPro has been shown to accelerate the growth of a broad spectrum of probiotic species, including:


  • B. bifidum
  • B. breve
  • B. animalis
  • B. longum
  • L. acidophilus
  • L. paracasei
  • L. casei
  • L. rhamnosus
  • Lc. lactis
  • B. subtilis

Figures 1 & 2 show the difference in growth rate of beneficial Bacillus subtilis and Lactococcus lactis bacteria after the introduction of undesirable E.coli bacteria.

B. subtilis growth after 5 hours under physiological conditions, competing with E. coli

Functions in Both Small and Large Intestine

In-vivo growth of beneficial bacteria, B. longum, when competing with undesirable bacteria, E. coli, in different sections of the gastrointestinal tract of mice that were administered PreforPro.

Lactococcus lactis growth after 5 hours under physiological conditions, competing with E. coli 

Human Clinical Study

In a human clinical study, PreforPro was shown to influence the microbial population of the gut, while also producing positive effects on cholesterol and immune response. Participants were administered one 15mg PreforPro capsule daily. When compared to the placebo group, results of the study indicated:

  • PreforPro substantially enhanced the growth of beneficial bacteria, including Bifidobacterium animalis, Lactobacillus delbrueckii and Lactobacillus lactococcus.
  • A significant decrease in LDL cholesterol was observed in the total study population, as well as a trend toward decreased total cholesterol.
  • Participants with excess lipids in the blood showed both clinically and statistically relevant decreases in total cholesterol and LDL cholesterol.
  • A significant decrease in the allergy-inducing interleukin 4 (IL-4) cytokine